ProMIS Neurosciences Inc PMN

Expecting tangible news soon

[Speyeder999]

Going through the last 6 months of PMN's news releases, I expect to see tangible evidence in the upcoming months that clinical trials will be underway in less than a year.  For instance, Promis should be  ramping up their staff just about now with job postings on their web site, announce the opening  of their Boston area facility as was announced in last years 20M public offerin and announce IND filings to FDA. 

The Company intends to use the net proceeds from the Offering to advance its lead Alzheimer’s therapy PMN310 to the filing of an Investigational New Drug (IND) application to enable a first clinical trial; to expand the Company’s portfolio of antibodies and patents; and for general corporate purposes, including, to establish a discovery laboratory in the Boston area, to accelerate and broaden the scope of the Company’s discovery efforts and to add additional scientific, administrative and support staff, all as further set out in the Supplement.

[goldtech]

There will be no lab in Boston this year and the only news will be the massive consolidation. All news will focus on PMN310 and the filings to get to clinical trials. The focus will be on results and then the market cap of a successful phase 1-2B.

[M101]

Yup, lab opening this year is not a priority ahead of P1 results. Why would the company take such a financial risk? But as for share consolidation before initial P1 results, I don't see the logic there either. We have cash through 2023, these moves will not be made until next year as early P1 results give clarity and rationale to the need.

[garygp]

M101, I agree with both you and goldtech and see both arguments. I’m wondering if management will do the consolidation sooner than later to get it out of the the way, get to the Nasdaq sooner, and have Promis established there so that when news flows in early 2023 we hit the ground running. I shudder everytime I think of the consolidation knowing Williams and Goldstein have sold us down the

[goldtech]

I wish that were true but Williams and Goldstein are still running the show. They keep screwing the shareholders and don't care because they have granted themselves options for years. Goldstein is being paid as a consultant to the Company and if you want to stop all this corruption then Williams has to be replaced and a new stronger board put in place. Can you imagine how poorly managed this

[M101]

So sweep it under the rug before starting the uplisting hype, manipulating price to a post-consolidation floor just above $US 5.00, perfect for attracting select new investors prior to the actual listing which ends up after early P1 results closer to $US 10.00. Ouch, that seems entirely plausible and consistent with the way Golstein timed financings. But the net result is the same as the Boston

[garygp]

I understand that doing a consolidation later would be to our advantage if the share price were allowed to somehow rise, and a rising sp is highly unlikely under new guidance.  The FSG are the new masters and the two clowns, Goldstein and Williams are the new messengers.  This collective group are all about 'them" and could give two sh*ts about us. We as shareholders are like

[M101]

So why wait? Because things can always get worse, disaster capitalism is coming home to the USA. Normal risk management practices imply that FSG is waiting for some confirmation of their early investment, they can do that here and still be ahead of momentum investors when time comes to double down because retail investors are not looking for biomarker success as defined by some esoteric medical